CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue	$ 0	$ 241	$ 320	$ 1,597
Operating expenses:
Research and development	17,416	9,028	49,721	22,530
General and administrative	3,076	2,803	9,477	7,523
Total operating expenses	20,492	11,831	59,198	30,053
Loss from operations	(20,492)	(11,590)	(58,878)	(28,456)
Other income (expense):
Loss from remeasurement of development derivative liability	(4,273)	0	(8,435)	0
Interest income	3	451	235	1,259
Interest expense	(362)	(266)	(1,119)	(711)
Foreign exchange gain (loss)	(19)	14	7	(8)
Total other income (expense)	(4,651)	199	(9,312)	540
Net loss	$ (25,143)	$ (11,391)	$ (68,190)	$ (27,916)
Net loss per common share, basic and diluted (in usd per share)	$ (0.86)	$ (0.40)	$ (2.36)	$ (1.03)
Weighted average common shares outstanding, basic, and diluted (in shares)	29,243,181	28,719,932	28,941,669	27,065,774
Grant Revenue
Revenue:
Revenue	$ 0	$ 241	$ 320	$ 1,097
Collaborative Agreement
Revenue:
Revenue	$ 0	$ 0	$ 0	$ 500